Northern Oil and Gas reports Q1 2026 results today with nearly a fifth of its free float held short — a level that has barely budged for weeks.
Short interest is running at roughly 17.7% of the free float, placing NOG firmly among the more shorted names in the E&P space. That position has been sticky: the 30-day change is just over 3%, and the week-on-week move is negligible. The ORTEX short score of 68.3 puts NOG in the bottom 4th percentile of its universe — meaning the short-side pressure here is more concentrated than almost all peers. Borrow, however, remains cheap at 0.43% annualised, down around 6% over the past month. Availability has loosened relative to the 52-week trough, suggesting the lending pool is not yet under meaningful stress. Days to cover from the most recent FINRA data stands at 8.7 — a number that frames just how long a covering event would take against normal trading volumes.
Options traders are mildly more cautious than usual, but not dramatically so. The put/call ratio is 0.67, about 0.8 standard deviations above its 20-day average of 0.58. That's a modest lean toward hedging, not a defensive surge — and it sits well below the 52-week high of 1.07. Peers including OVV, , and have each gained 6–8% on the week, broadly in line with NOG's own 7.8% bounce from $27.56, suggesting the recent recovery is sector-wide rather than stock-specific.
The bull and bear debate centres on production and capital efficiency. Bulls point to a revised capex plan of $250–300 million for FY26, a reinvestment rate of ~79%, and projected leverage of 1.6x — manageable by most E&P standards. Bears focus on a sharp downward revision to production guidance: FY26 oil output is now expected around 73.9 mbbls/d, down from prior estimates near 84 mbbls/d. That gap matters more than the leverage, because the EV/FCF yield on current strip pricing — ~9.2% for FY26 — trails the SMID E&P peer median of ~15.9%. Analyst targets cluster in the low-to-mid $30s; Citi maintained its Buy but cut its target to $36 from $39 in mid-April, while BofA held Buy with a $32 target. Morgan Stanley remains the outlier with an Underweight and a $24 target. The mean target of ~$35.67 implies roughly 29% upside from current levels, though the divergence in ratings reflects genuine disagreement rather than consensus drift.
One detail worth noting ahead of the print: on March 16, the CEO, CFO, President, CTO, and Chief Legal Counsel all sold shares on the same day, with the CEO disposing of ~$689,000 worth. The net 90-day insider position is positive at roughly $2.9 million, with the February awards to the CFO accounting for most of that offset. The cluster sale at current price levels is a data point the market will weigh against whatever guidance tone management delivers today.
The Q1 report will test whether the production revision was a one-time reset or the opening move in a longer downgrade cycle — and whether a sub-10% FCF yield can hold analyst support when the rest of the sector trades at a meaningful premium.
See the live data behind this article on ORTEX.
Open NOG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
